Month: April 2023

Dr. Paul Peter Tak was included in ‘the Medicine Maker Power List 2023’

The Medicine Maker Power List 2023

Celebrating 30 influential and inspirational leaders across small molecule, biopharmaceutical, and cell and gene therapy development and manufacture

The Medicine Maker is what it is because of its connection and collaboration with a vast network of industry experts. Whether speaking with seasoned CEOs, academic experts, or bench scientists, we are here to share stories and perspectives on what the industry could become – for patients and the planet.

Working alongside both new and ongoing challenges, including the COVID-19 pandemic and emerging threats to global health, online and media scrutiny, climate change, and a charged political worldscape, inspirational thought leaders continue to emerge and change the ways in which the pharma industry operates.

We asked readers to nominate the people enabling progress in the small molecule, biopharmaceutical, and advanced therapy spaces. Now, we invite you to join us as we celebrate the top 10 leaders in each.

Paul-Peter Tak

Tak is ranked at 150 in the 2022 world ranking of top 1,000 scientists in immunology and was elected Fellow of the Academy of Medical Sciences, UK. He has served as Senior Vice President, Chief Immunology Officer, and Global Development Lead at GSK, where he oversaw the creation of a portfolio of new medicines. He then cofounded Sitryx Therapeutics and led Tempero Pharmaceuticals (acquired by GSK) and Kintai Therapeutics (merged with Senda Biosciences) as CEO.

At Candel Therapeutics, he brought together a world-class executive team, prioritized the portfolio, initiated the new enLIGHTENTM Discovery Platform, created a high-profile Research Advisory Board, and led the company to an IPO on the NASDAQ. Candel has recently presented proof of concept for its viral immunotherapies across multiple solid tumors.  

Podcast: Developing Novel viral Immunotherapies to Improve Cancer Outcomes

Join us in this eye-opening YouTube video as we introduce Dr. Paul Peter Tak, a trailblazer in the field of biotechnology and the President, Chief Executive Officer, and a Board member of Candel Therapeutics. Dive into the world of ground-breaking viral immunotherapies designed to induce immunogenic cell death within cancer cells right at the injection site. Dr. Tak leads the charge in developing and commercializing these novel therapies, emphasizing the unmasking of tumour neo-antigens within an activated microenvironment. Discover how this strategic approach aims to trigger a systemic, enduring immune response against tumours, with the potential to revolutionize outcomes across a spectrum of indications. Don’t miss out on this exclusive insight into the future of cancer treatment and the game-changing work at Candel Therapeutics. Subscribe now and stay at the forefront of cutting-edge medical advancements!

Paul Peter Tak

© Paul Peter Tak.
All rights reserved.